Exclusive: Shire- Baxalta combined 2015 revenue seen at $12.4 billion

5 August 2015
mergers-acquisitions-big

The combined revenue for the entity following the merger of Shire (LSE: SHP) and Baxalta (NYSE: BXLT) will hit $12.4 billion in 2015, according to analysts.

Pharma-orientated financial research firm Evaluate has pegged the overall revenue growth at $18 billion by 2020. Shire has put the estimates at $20 billion for the same period.

The overall growth is estimated at the rate of 7% by 2020 for the combined group.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology